Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis

被引:90
作者
Kröger, N [1 ]
Zabelina, T [1 ]
Schieder, H [1 ]
Panse, J [1 ]
Ayuk, F [1 ]
Stute, N [1 ]
Fehse, N [1 ]
Waschke, O [1 ]
Fehse, B [1 ]
Kvasnicka, HM [1 ]
Thiele, J [1 ]
Zander, A [1 ]
机构
[1] Univ Hosp Cologne, Inst Pathol, Cologne, Germany
关键词
myelofibrosis; reduced-intensity conditioning; donor lymphocyte infusion; graft-versus-host disease; graft failure;
D O I
10.1111/j.1365-2141.2005.05373.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A prospective pilot study was performed to evaluate the effect of reduced-intensity conditioning with busulphan (10 mg/kg), fludarabine (180 mg/qm) and anti-thymocyte globulin followed by allogeneic stem cell transplantation from related (n = 8) and unrelated donors (n = 13) in 21 patients with myelofibrosis. The median age of the patients was 53 years (range, 32-63). No primary graft failure occurred. The median time until leucocyte (>1.0 x 10(9)/l) and platelet (>20 x 10(9)/l) engraftment was 16 (range, 11-26) and 23 d (range, 9-139) respectively. Complete donor chimaerism on day 100 was seen in 20 patients (95%). Acute graft-versus-host disease (GvHD) grades II-IV and III/IV occurred in 48% and 19% of cases and 55% of the patients had chronic GvHD. Treatment-related mortality was 0% at day 100 and 16% [95% confidence interval (CI): 0-32%] at 1 year. Haematological response was seen in 100% and complete histopathological remission was observed in 75% of the patients and 25% of the patients showed partial histopathological remission with a continuing decline in the grade of fibrosis. After a median follow-up of 22 months (range, 4-59), the 3-year estimated overall and disease-free survival was 84% (95% CI: 67-100%).
引用
收藏
页码:690 / 697
页数:8
相关论文
共 39 条
[31]   Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation [J].
Nagler, A ;
Aker, M ;
Or, R ;
Naparstek, E ;
Varadi, G ;
Brautbar, C ;
Slavin, S .
EXPERIMENTAL HEMATOLOGY, 2001, 29 (03) :362-370
[32]   THE VERY-LONG-TERM COURSE OF POLYCYTHEMIA - A COMPLEMENT TO THE PREVIOUSLY PUBLISHED DATA OF THE POLYCYTHEMIA-VERA STUDY-GROUP [J].
NAJEAN, Y ;
DRESCH, C ;
RAIN, JD .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 86 (01) :233-235
[33]  
PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825
[34]  
RONDELLI D, 2003, BLOOD, V102
[35]   Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases [J].
Slavin, S ;
Nagler, A ;
Naparstek, E ;
Kapelushnik, Y ;
Aker, M ;
Cividalli, G ;
Varadi, G ;
Kirschbaum, M ;
Ackerstein, A ;
Samuel, S ;
Amar, A ;
Brautbar, C ;
Ben-Tal, O ;
Eldor, A ;
Or, R .
BLOOD, 1998, 91 (03) :756-763
[36]   Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis [J].
Thiele, J ;
Kvasnicka, HM ;
Schmitt-Graeff, A ;
Diehl, V .
HISTOPATHOLOGY, 2003, 43 (05) :470-479
[37]   Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): A retrospective clinicopathological study of 120 patients [J].
Thiele, J ;
Kvasnicka, HM ;
Schmitt-Graeff, A ;
Zankovich, R ;
Diehl, V .
AMERICAN JOURNAL OF HEMATOLOGY, 2002, 70 (04) :283-291
[38]   MYELOFIBROSIS WITH MYELOID METAPLASIA - CLINICAL AND HEMATOLOGICAL PARAMETERS PREDICTING SURVIVAL IN A SERIES OF 133 PATIENTS [J].
VISANI, G ;
FINELLI, C ;
CASTELLI, U ;
PETTI, MC ;
RICCI, P ;
VIANELLI, N ;
GIANNI, L ;
ZUFFA, E ;
SPIRITI, MAA ;
LATAGLIATA, R ;
PILERI, S ;
MAGRINI, U ;
GUGLIOTTA, L ;
MORRA, E ;
BERNASCONI, C ;
MANDELLI, F ;
TURA, S .
BRITISH JOURNAL OF HAEMATOLOGY, 1990, 75 (01) :4-9
[39]   ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML) [J].
Zander, AR ;
Kröger, N ;
Schleuning, M ;
Finke, J ;
Zabelina, T ;
Beelen, D ;
Schwerdtfeger, R ;
Baurmann, H ;
Bornhäuser, M ;
Ehninger, G ;
Fauser, AA ;
Kiehl, M ;
Trenschel, R ;
Ottinger, HD ;
Bertz, H ;
Berger, J ;
Kolb, HJ ;
Schaefer, UW .
BONE MARROW TRANSPLANTATION, 2003, 32 (04) :355-361